What Is Hexarelin Peptide?
Hexarelin Peptide, also known as examorelin, is a synthetic hexapeptide belonging to the growth hormone secretagogue family. It is classified as a peptide compound with a structure designed to interact with growth hormone secretagogue signaling systems. Hexarelin is one of the synthetic peptides developed from research into growth hormone-releasing peptides and their biological receptors.
The compound appears in scientific literature as a research molecule used to investigate growth hormone secretagogue activity and related endocrine signaling. Early studies characterized Hexarelin as a synthetic hexapeptide and examined its ability to interact with specific growth hormone secretagogue receptors. Research has also helped define the receptor systems associated with this class of compounds.
Hexarelin has therefore become a subject of research in peptide biology, receptor pharmacology, and endocrine signaling. Its published literature includes experimental and clinical research. The evidence base is not predominantly preclinical.
Research Overview Table
Chemical and Molecular Characteristics
Hexarelin is a synthetic hexapeptide made up of six amino acid residues. Its structure contains D-2-methyltryptophan at the second position and D-phenylalanine at the fifth position along with a C-terminal lysinamide group. These structural features give Hexarelin its distinct molecular structure and are part of its chemical identity.
The molecular formula of Hexarelin is C₄₇H₅₈N₁₂O₆, with a molecular weight of 887.0 g/mol. Its structure contains peptide bonds along with nitrogen- and oxygen-containing groups contributed by its amino acid residues. These features make up the chemical composition of the peptide and provide its basic molecular characteristics.
Certificates:
Mechanism of Action Under Investigation
Hexarelin has been investigated primarily through its interaction with the growth hormone secretagogue receptor (GHS-R1a), a seven-transmembrane G protein-coupled receptor. Experimental research shows that activation of GHS-R1a by Hexarelin engages the phospholipase C (PLC) pathway, with a subsequent increase in intracellular calcium. These calcium responses have been used experimentally to measure receptor activation and desensitization following Hexarelin exposure.
Studies in isolated cardiac cells have further investigated downstream signaling. The Hexarelin-associated increase in calcium current was reduced by a GHS-R1a antagonist and by a protein kinase C (PKC) inhibitor supporting involvement of GHS-R1a and PKC signaling in that experimental system.
Hexarelin has also been shown to bind CD36. Researchers used a radiolabeled photoactivatable Hexarelin derivative competitive binding experiments, and chemical and enzymatic fragmentation to identify a Hexarelin-binding region within CD36. This provides experimental evidence for an additional molecular interaction, although its significance relative to GHS-R1a signaling remains under investigation.
Scientific Research Context
Hexarelin has been studied in cell-based, animal, and human research. giving the compound a broad experimental evidence base. Early research focused on its initial characterization, followed by studies in animal models and controlled human settings. Most of the available evidence comes from in vitro and animal research, while human studies make up a smaller part of the evidence base. This makes Hexarelin a relatively well-studied experimental peptide, although the overall literature remains primarily preclinical.
Hexarelin Biology and Biological Pathways
Primary Biological Function
The growth hormone secretagogue receptor (GHS-R) is part of the endocrine signaling system that regulates growth hormone. GHS-R1a is expressed in the pituitary and hypothalamus with receptor binding also identified in several peripheral tissues. Researchers study this receptor system to understand its biological distribution and role across different tissues.
Relevant Signaling Pathways
Hexarelin-related research has examined signaling within the GHS-R system, including phospholipase C (PLC), intracellular calcium, and protein kinase C (PKC). In experimental cells, Hexarelin produced calcium responses through GHS-R activation. Studies in rat skeletal and cardiac muscle also found that PLC and PKC inhibitors altered Hexarelin-associated cellular responses. Research has additionally examined the interaction between Hexarelin, growth hormone-releasing hormone, and somatostatin in endocrine studies. These pathways are investigated to characterize the cellular and endocrine signaling associated with Hexarelin.
Tissue-Specific Biology
GHS-R binding sites have been identified in the pituitary, hypothalamus, heart, adrenal glands, gonads, blood vessels, lungs, liver, skeletal muscle, kidneys, and adipose tissue. The distribution is not uniform across tissues. Studies using human tissue samples have therefore been important for mapping where GHS-related receptors are present and for examining possible tissue-specific roles.
Experimental Biomarkers
Researchers studying Hexarelin have measured growth hormone (GH), prolactin (PRL), ACTH and cortisol in blood samples. Studies have also examined GHS-R1a mRNA expression in pituitary and hypothalamic tissue. These markers give researchers measurable data for assessing endocrine responses and receptor expression in different experimental settings.
Laboratory Investigation Methods
Hexarelin-related studies have used RT-PCR, ligand-binding assays, radiolabeled peptide binding, and intracellular calcium measurements. RT-PCR has been used to examine GHS-R1a mRNA expression while radiolabeled Hexarelin derivatives have been used to characterize binding sites. Calcium measurements have been used to assess changes in intracellular calcium in experimental cells.
Experimental Models Used in Published Research
Hexarelin has been investigated in cultured pituitary cells, rat models, isolated rat heart preparations, and human studies. These experimental models include both isolated biological systems and intact organisms. Each has limitations, including the restricted biological context of cell and organ preparations, species differences in animal models, and the limited scope of controlled human studies.
Pituitary Cell Models
Hexarelin has been studied in rat pituitary cells, GH1 cells, and cultured human pituitary somatotrophs. These cell models isolate pituitary tissue from the rest of the endocrine system. That makes them useful for cell-level research, but they cannot capture the interactions between the pituitary, hypothalamus, and peripheral tissues that occur in an intact organism.
Rat Models
Infant, young adult, aged, and GHRH-impaired rats have been used in Hexarelin research. These models allow studies in an intact mammalian system and include both normal and experimentally altered endocrine states. Their main limitation is the physiological difference between rats and humans, which can limit how directly findings from these models apply to human biology.
Isolated Rat Heart Models
Isolated perfused rat hearts have been used as an organ-level model in Hexarelin research. This preparation allows the heart to be examined separately from the rest of the body under defined experimental conditions. Its main limitation is that an isolated heart cannot reproduce interactions with circulating hormones, blood flow, or other organs.
Human Studies
Healthy adult volunteers and patients with endocrine or pituitary disorders have been included in controlled Hexarelin studies. Human studies provide a model based directly on human physiology, but the available research generally involves small, selected groups and controlled experimental conditions. These factors limit how broadly findings from individual studies can be generalized.
Hexarelin Published Research
Growth Hormone Secretion
A major area of Hexarelin research has been growth hormone secretion. Studies have examined GH responses across different doses, administration routes, ages, and endocrine conditions. Research has also compared Hexarelin with GHRH and examined how GH responses vary in different hypothalamic-pituitary conditions.
Pituitary Hormone Regulation
Hexarelin has been investigated in relation to prolactin, ACTH, and cortisol, in addition to growth hormone. Studies have examined these hormonal responses under different endocrine conditions, including differences related to age and pituitary or adrenal disorders. This research has helped characterize the broader endocrine responses associated with Hexarelin.
GHS-R1a Receptor Biology
Studies have examined GHS-R1a receptor expression, ligand binding, receptor activation, and desensitization in relation to Hexarelin. Researchers have also measured GHS-R1a mRNA in pituitary and hypothalamic tissue and examined how receptor expression changes under different experimental conditions.
CD36 and Cardiovascular Research
Another research area concerns CD36 and cardiovascular biology. Studies have investigated Hexarelin binding to CD36 and examined the presence of Hexarelin-related receptor activity in cardiac tissue. This line of research expanded the investigation beyond the pituitary and hypothalamic systems.
Limitations of Current Research
Evidence Is Predominantly Preclinical
Most of the Hexarelin literature comes from preclinical studies, particularly cellular and animal research. Human studies are also available, so describing the evidence as entirely preclinical would be inaccurate. The current evidence base therefore includes both preclinical and human research.
Human Clinical Evidence
The human evidence remains limited by small sample sizes and restricted study populations. These limitations make it difficult to determine how consistently the findings apply beyond the specific groups and experimental conditions examined in the available studies.
Species Differences
Differences in endocrine regulation and receptor biology across species can affect responses to Hexarelin. Findings observed in one species may therefore not translate directly to humans. This makes species-specific biology an important limitation when interpreting preclinical evidence and its relevance to human physiology.
Study Design Limitations
Differences in dose, administration route, dosing interval, and study duration make the published Hexarelin studies difficult to compare. Researchers have used both single-dose and repeated-dose protocols with different intervals between administrations. This variation makes it harder to separate Hexarelin effects from study-design differences.
Independent Replication
The evidence base is relatively specialized, and independent replication is uneven across research areas. Some findings have been examined in multiple studies while other observations come from a smaller number of investigations.
Long-Term Evidence
Long-term evidence remains limited despite studies lasting 16 weeks and up to 6–10 months. The longer studies involved small numbers of participants as the available data provide only a narrow view of prolonged Hexarelin exposure. Evidence covering longer periods and larger populations remains limited.
Analytical Documentation
HPLC can assess the chromatographic profile and purity of a Hexarelin preparation. Chromatographic analysis can help identify differences between the expected and observed sample profile.
LC-MS adds mass measurement to chromatographic separation. Published analytical research has used LC-MS/MS to identify Hexarelin and its metabolites supporting identity and analytical detection.
NMR can provide detailed structural information about peptides, but it is not necessary for every Hexarelin analysis. Its use depends on the purpose and scope of the characterization.
A Certificate of Analysis (COA) summarizes analytical testing performed on a particular batch. For laboratory research, this documentation helps establish the identity, purity, and tested characteristics of the material.
Analytical documentation supports product identity and quality; it does not demonstrate biological performance.
Storage and Laboratory Handling
Store Hexarelin according to the specifications supplied with the product. The provided Certificate of Analysis lists 2–8°C for storage. Keep the material sealed and protected from moisture, heat, and unnecessary exposure to light. Avoid repeated temperature changes that could affect the integrity of the material.
Qualified laboratory personnel should handle the material in a clean laboratory environment. Keep the container sealed when not in use and use appropriate contamination control practices. Maintain accurate batch and storage records throughout laboratory handling.
Frequently asked questions
Why choose us?
Direct SARMs is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.
Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.
Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs, we aim to make the research supply process simple, clear, and reliable.